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ABSTRACT 
Background and Objectives: High-dose intravenous immunoglobulin (IVIG) (2 g/kg) is usually given in the 
treatment of Kawasaki disease (KD). According to the authors’ experience, however, medium-dose immuno-
globulin (1 g/kg) was also effective in the majority of patients. We performed a retrospective clinical study to 
validate effectiveness of the medium-dose regimen in treatment of KD. Subjects and Methods: A total of 274 pa-
tients with KD who were treated with medium-dose immunoglobulin at Bundang Jesaeng General Hospital 
from July 1998 to October 2007 were enrolled. Results: Medium-dose immunoglobulin was given once in 220 
patients (group A; 80.3%) and twice or more in 54 patients (group B; 19.7%). Age and gender distributions, 
duration of fever before treatment, hemoglobin concentrations, and white blood cell and platelet counts did not 
differ significantly between the two groups (p>0.05). Concentrations of C-reactive protein, aspartate aminotrans-
ferase, alanine aminotransferase, and bilirubin were significantly higher in group B (p<0.005). Coronary arterial 
lesions (CAL) were found in 51 patients (23.2%) in group A and in 26 patients (48.1%) in group B during the 
acute stage, and in 14 patients (6.4%) in group A and in 11 patients (20.4%) in group B during the convalescent 
stage (p<0.005, respectively). A giant aneurysm was found in one patient in each group (0.5% in group A and 
1.9% in group B; p<0.005) during the follow-up period. Conclusion: A single infusion of medium-dose im-
munoglobulin was effective in 80% of patients with KD. About 20% of patients required two or more infusions 
of medium-dose immunoglobulin, who had higher concentrations of C-reactive protein, aspartate aminotransferase, 
alanine aminotransferase and bilirubin. The authors think that the medium-dose regimen proffers an advantage 
over the high-dose regimen in view of cost-effectiveness. (Korean Circ J 2010;40:81-85) 
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Introduction 
 
Kawasaki disease (KD) is an acute febrile exanth-
ematous illness involving development of vasculitis in 
various tissue and organs, and frequently affects coro-
nary arteries and cardiac tissue, causing coronary ectasia 
or aneurysm, myocarditis, valvulitis, and pericarditis.
1) 
KD is now the most important cause of acquired heart 
disease in infants and children.
2) These days, treatment 
of KD consists of intravenous immunoglobulin (IVIG) 
and oral aspirin, and IVIG is usually administered as a 
single infusion of 2 g/kg (high-dose IVIG).
1) However, 
some clinical studies have shown that a single infusion 
of IVIG 1 g/kg (medium-dose IVIG) was also effec-
tive.
3-7) Since the 1990s, Han et al.
8) has administered 
medium-dose IVIG as the initial treatment for patients 
with KD, giving one more infusion after 48 hours if fever 
persisted, and results that such a mediumdose regimen 
have been good.   
The cost of IVIG is high (about 40,000-45,000 won/ 
2.5 g). For a patient weighing 20 kg and receiving high-
dose IVIG, the cost of IVIG is about 640,000-720,000 
won. If the patient receives medium-dose IVIG, the cost 
will be reduced to 320,000-360,000 won. Therefore, the 
authors think that the medium-dose regimen proffers an 
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advantage over the high-dose regimen in view of cost-
effectiveness, if the two regimens are equally effective. 
We therefore performed a retrospective clinical study 
to validate effectiveness of the medium-dose regimen in 
treatment of KD. 
 
Subjects and Methods 
 
Two hundred seventy four patients (162 males and 
112 females; M：F=1.45：1) with KD were admitted 
to Bundang Jesaeng General Hospital from July 1998 
to October 2007. The proportion of patients with KD 
was 1.57% of all patients admitted to the pediatric ward 
(with the exception of the neonatal unit) of the hospi-
tal during the study period. Diagnosis of KD was based 
on the presence of fever for 5 days or more and presen-
tation with 4 or more of 5 principal clinical features 
(bilateral bulbar conjunctival injection; changes in lips, 
tongue, or oral mucosa; cervical lymphadenopathy gr-
eater than 1.5 cm in diameter; polymorphous skin rash; 
changes in extremities).
9) In cases where a patient had 
fever for 7 days or more, and 3 or less of 5 principal cli-
nical features, and other diseases were excluded, echo-
cardiography was performed. If findings on echocar-
diography were abnormal {coronary arterial lesions (CAL), 
decreased ventricular systolic function, significant val-
vular regurgitation, and pericardial effusion}, the patient 
was diagnosed as having KD.
1) CAL included ectasia 
and aneurysm. Normal internal diameters of coronary 
arteries were defined as 2.5 mm or less in infants less 
than 1 year old, 3 mm or less in children from 1 to 4 
years old, and 4 mm or less in children 5 years or older. 
Significant valvular regurgitation was defined as mitral 
or aortic valvular regurgitation of grade 1 or more and 
tricuspid or pulmonary valvular regurgitation of grade 
2 or more, according to the previous study.
10) 
Medium-dose IVIG (1 g/kg) was infused over 8-10 
hours as the initial treatment as soon as the diagnosis 
of KD was made. If fever did not subside within 48 
hours, one more infusion of medium-dose IVIG was 
given. If fever persisted or relapsed thereafter, one or 
more infusions of medium-dose IVIG was given again. 
Aspirin (30-50 mg/kg/day) was given orally in 3 di-
vided doses from the time of diagnosis until one week 
after defervescence; the dosage was then reduced to 3-
5 mg/kg/day in a single dose. 
Patients treated with a single infusion of mediumdose 
IVIG were defined as group A, and patients treated with 
two or more infusions were defined as group B. Patient 
characteristics in both groups were compared; these in-
cluded demographic features, duration of fever before 
and after treatment, laboratory findings, and rates of 
CAL. Continuous variables were described as mean±
standard deviation. Statistical analyses were performed 
by means of the Student t-test for continuous variables 
and the Chi-square test for rates and proportions. P of 
less than 0.05 was considered statistically significant. 
 
Results 
 
Among 274 patients, 220 of them showed improve-
ment with a single infusion of medium-dose IVIG 
(group A; n=220; 80.3%). Forty one patients showed 
improvement with two infusions, 11 patients showed 
improvement with three infusions, and two patients 
showed improvement with four and five infusions each 
(group B; n=54; 19.7%). Male-to-female ratios (1.37：
1 in group A vs. 1.84：1 in group B), age distributions 
(33.8±25.2 vs. 35.9±29.4 months), duration of fever 
before treatment (5.6±1.8 vs. 5.0±1.8 days), hemo-
globin concentrations (11.2±1.0 vs. 11.4±0.8 g/dL), 
white blood cell counts (15,010±5,370 vs. 15,570±
5,580/mcL), and platelet counts (374,000±126,200 vs. 
358,500±138,100/mcL) did not differ significantly be-
tween the two groups (p>0.05) (Table 1).  
Duration of fever after treatment was significantly 
longer in group B than in group A (0.5±0.8 days in 
group A vs. 4.5±2.6 days in group B), and concen-
Table 1. Comparison of demographic features and laboratory findings in each group
  Group A (n=220)  Group B (n=54)  p 
Male : Female  127：93 (1.37：1) 35：19 (1.84：1)  >0.05
Age (month)  33.8±25.2 35.9±29.4  >0.05
Duration of fever       
Before treatment (day)  5.6±1.8 5.0±1.8  >0.05
After treatment (day)  0.5±0.8 4.5±2.6  <0.005
Hemoglobin (g/dL)  11.2±1.0 11.4±0.8  >0.05
White blood cell (/mcL)  15,010±5,370 15,570±5,580  >0.05
Platelet (/mcL)  374,000±126,200 358,500±138,100  >0.05
CRP (mg/dL)  8.7±5.4 12.1±5.7  <0.005
AST (U/L)  69.2±110.8 150.4±245.7  <0.005
ALT (U/L)  82.7±111.2 156.3±202.4  <0.005
Bilirubin (mg/dL)  0.5±0.7 1.1±1.4  <0.005
CRP: C-reactive protein, AST: aspartate aminotransferase, ALT: alanine aminotransferase 
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trations of C-reactive protein (8.7±5.4 vs. 12.1±5.7 
mg/dL), aspartate aminotransferase (69.2±110.8 vs. 
150.4±245.7 U/L), alanine aminotransferase (82.7±
111.2 vs. 156.3±202.4 U/L), and total bilirubin (0.5
±0.7 vs. 1.1±1.4 mg/dL) were significantly higher in 
group B than in group A (p<0.005, respectively) (Table 1). 
CAL were found in 51 patients (23.2%) in group A 
and 26 patients (48.1%) in group B who were in the 
acute stage (p<0.005). CAL were found in 14 patients 
(6.4%) in group A and 11 patients (20.4%) in group B 
who were in the convalescent stage (p<0.005). During 
the follow-up period, CAL disappeared in 13 of 14 pa-
tients in group A and in 7 of 11 patients in group B. A 
giant aneurysm of 8 mm or more in diameter was found 
in one patient in each group (0.5% in group A and 1.9% 
in group B; p<0.005) (Table 2). Three patients in group 
B were lost to follow-up.  
 
Discussion 
 
Suppression of acute inflammatory reactions and pre-
vention or reduction of cardiac complications, such as 
coronary aneurysm are the goals of treatment in KD. 
Efficacy of IVIG in treatment of KD was first reported 
in 1984.
11) IVIG was given at the dosage of 400 mg/kg/ 
day for 3-5 consecutive days during the earlier period. 
It was reported years later that a single infusion of IVIG 
2 g/kg suppressed acute symptoms of KD more rapidly, 
decreased duration of both intravenous injection and 
hospitalization, and effectively prevented coronary an-
eurysm.
12-14) Thereafter, a single infusion of high-dose 
IVIG became the standard regimen in treatment of KD 
(the high-dose regimen). 
Opinions have differed, however, on the effective 
dosage of IVIG in treatment of KD. Engle et al.
3) re-
ported that a single infusion of IVIG 1 g/kg was ef-
fective in treatment of KD, and Furusho et al.
4) sug-
gested that the dosage of IVIG should be 1 g/kg or more 
for effective prevention of CAL. Barron et al.
5) com-
pared effectiveness of a single infusion of IVIG 1 g/kg 
and infusions of 400 mg/kg/day for 4 days and re-
ported that a single infusion of 1 g/kg suppressed fever 
more rapidly and prevented coronary aneurysm with 
equal effectiveness. Ihn et al.
6) and Qin et al.
7) com-
pared effectiveness of IVIG 1 g/kg and 2 g/kg and re-
ported that the two regimens were equally effective. Han 
et al.
8) performed a clinical study to evaluate effectiveness 
of medium-dose IVIG during the 1990s. Results from 
that study showed improvement in 86% of patients with 
a single infusion of IVIG 1 g/kg and 14% showed im-
provement with two infusions of IVIG 1 g/kg. Rates of 
coronary aneurysm showed no significant difference 
from each other or from patients treated with a single 
infusion of IVIG 2 g/kg. Therefore, Han et al.
8) thoug-
ht that medium-dose IVIG was effective in the ma-
jority of patients with KD and that the mediumdose 
regimen was more advantageous than the highdose re-
gimen in view of cost-effectiveness. 
KD shows various degrees of severity and ranges from 
a mild illness that subsides quickly without complica-
tions to a very severe illness that is complicated by se-
rious complications and can be fatal. Several scoring 
systems have been developed to identify patients at hi-
gher risk for coronary aneurysm so that they can be tr-
eated more aggressively. However, the scoring systems 
are not accurate, and their application in clinical prac-
tice is somewhat cumbersome. Therefore, the authors 
recommend the medium-dose regimen in which a sin-
gle infusion of IVIG 1 g/kg is given as the initial treat-
ment. A single infusion of medium-dose IVIG will be 
sufficient for the majority of patients suffering mildto-
moderate KD, and one or more additional infusions 
can be given to the minority of patients who suffer se-
vere KD and do not respond to a single infusion of me-
dium-dose IVIG. 
In this study, 80% of patients showed improvement 
with a single infusion of IVIG 1 g/kg (group A) and 
20% showed improvement with two or more infusions 
of IVIG 1 g/kg (group B). These results were similar to 
those of the previous study by Han et al.
8) Demogra-
phic features, duration of fever before treatment, hemo-
globin concentrations, and white blood cell and plate-
let counts did not differ significantly between two groups. 
However, concentrations of C-reactive protein, aspartate 
aminotransferase, alanine aminotransferase, bilirubin, 
and rates of CAL were significantly higher in group B 
than in group A. It can be postulated that patients in 
group A suffered mild-to-moderate illness and patients 
in group B suffered severe illness. So the latter might 
require greater amounts of IVIG for suppression of more 
severe inflammatory reactions, and therefore develop 
CAL more frequently than the former. Therefore, the 
authors insist that even a single infusion of medium-
dose IVIG is effective in the majority (about 80%) of 
patients, and one or more additional infusions are 
needed only in a minority (about 20%) of patients who 
do not respond to a single infusion of medium-dose 
IVIG. Use of the medium-dose regimen will reduce the 
cost of treatment by 40% roughly, compared with use 
of the high-dose regimen. 
Some may have questions regarding the accuracy of 
diagnosis of KD in patients enrolled in this study. The 
Table 2. Rates of coronary arterial lesions in each group
  Group A 
(n=220) (%) 
Group B 
(n=54)(%)  p 
Acute stage  51 (23.2)  26 (48.1)  <0.005
Convalescent stage  14 (6.4)0 11  (20.4)  <0.005
Follow-up period  1 (0.5)*  1 (1.9)*  <0.005
*giant aneurysm 
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authors made their diagnoses based on currently ap-
proved diagnostic criteria.
1)9) The proportion of patients 
with KD was 1.57% of all patients admitted to the pe-
diatric ward (with the exception of the neonatal unit) 
of Bundang Jesaeng General Hospital during the study 
period. This proportion was similar to the mean pro-
portion of patients with KD (1.48%) in a recent na-
tionwide survey.
15) Therefore, the authors think that the 
diagnosis of KD in patients enrolled in this study was 
accurate. 
In this study, the authors defined normal internal 
diameters of coronary arteries as 2.5 mm or less in in-
fants less than 1 year old, 3 mm or less in children from 
1 year to 4 years old, and 4 mm or less in children 5 
years or older. The Japanese Ministry of Health de-
fines normal internal diameters of coronary arteries as 
3 mm or less in children 4 years or younger and 4 mm 
or less in children 5 years or older.
16) In the opinion of 
the authors, however, the criteria of the Japanese Mi-
nistry of Health are too simple and may underestimate 
of rates CAL in small infants. Nakano et al.
17) and de 
Zorzi et al.
18) proposed that normal internal diameters 
of coronary arteries be 2.5 mm or less if body surface 
area (BSA) is less than 0.5 m
2, 2.5-3 mm if BSA is 0.5-
1 m
2, and 3 mm or more if BSA is 1 m
2 or more. Other 
criteria define normal internal diameters of coronary 
arteries as 2.5 mm or less in children weighing less than 
12.5 kg, 2.5-3 mm in children weighing between 12.5 
kg and 27.5 kg, and 3-5 mm in children weighing 27.5 
kg or more.
19) Therefore, the authors classified infants 
less than 1 year old separately, and, within this context, 
defined the normal internal diameter of coronary ar-
teries as 2.5 mm or less. Rates of CAL in this study were 
higher than those in other studies. The reasons for these 
results could be explained by the following: The authors 
included mild coronary ectasia into CAL, and more in-
fants may have been diagnosed with CAL by use of our 
detailed criteria on the normal diameter of coronary 
arteries in infants. 
The limitations of this study are that it is a retro-
spective study, and we evaluated treatment outcomes 
in patients treated with medium-dose IVIG, instead of 
comparing them with those in patients treated with 
high-dose IVIG. However, in the previous study by Han 
et al.
8) treatment outcomes in patients treated with 
medium-dose IVIG were similar to those in patients 
treated with high-dose IVIG.
8) Therefore, the authors 
think that effectiveness of medium-dose IVIG is con-
sistent and comparable with that of high-dose IVIG in 
the majority of patients with KD. In the minority of 
patients with severe KD, however, two or more infu-
sions of medium-dose IVIG will be required. In con-
clusion, the authors think that the regimen with me-
dium-dose IVIG (1 g/kg) is effective in the majority of 
patients with KD and proffers an advantage over the 
regimen with high-dose IVIG (2 g/kg) in view of cost-
effectiveness. 
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